Weitere vorgeschlagene Titel

Warenkorb

Sie werden jetzt wie ein VIP behandelt!

Durch den Abschluss einer Kobo VIP-Mitgliedschaft erhalten Sie 10 % Rabatt und doppelte Kobo Super Points auf ausgewählte Elemente.

Artikel nicht erhältlich
Bitte überprüfen Sie Ihren Warenkorb. Sie können nicht verfügbare Artikel jetzt entfernen. Andernfalls werden diese beim Bezahlen automatisch entfernt.
ElementeElement
Ihre persönlichen Empfehlungen
Ihre persönlichen Empfehlungen
Ihre persönlichen Empfehlungen
Bewertungen und Buchrezensionen (2 14 Sterne-Bewertungen
2 Bewertungen
)

Gesamtbewertung

4,4 aus 5
14
5 Sterne 4 Sterne 3 Sterne 2 Sterne 1 Stern
9 3 1 1 0

Teilen Sie Ihre Gedanken

Sie haben bereits eine Rezension für dieses Element geteilt. Vielen Dank!

Wir prüfen im Moment Ihren Beitrag. Vielen Dank!

Vervollständigen Sie Ihre Rezension

Alle Buchrezensionen

  • 1 Person fand diese Rezension hilfreich

    1 Personen fanden diese Rezension hilfreich

    1 von 1 Personen fand(en) diese Rezension hilfreich

    Danke für Ihr Feedback!

    Dense but lucid examination

    Ben Goldacre is a very angry man, with good reason. In this book he lays out how the pharmaceutical industry has distorted drug research in pursuit of profit, sometimes intentionally, sometimes entirely without malice but with equally devastating effects for patient welfare. This matters because patients are prescribed less effective drugs, or drugs which are outright harmful, at huge financial expense to those paying for the drugs. This isn’t a conspiracy theory book; Goldacre is quite clear that many valuable drugs have come out of the industry, and that most of the people who work in it want to make better drugs. He sets out in detail how and why bias is introduced into both research and prescribing practices, putting it in layman’s terms but linking to the research papers and court documents that back up what he’s saying. He also addresses the failings of the current regulatory system, and proposes ways to improve things — pointing out that unless real controls with serious financial penalties are put in place, even those companies which genuinely want to reform will be under commercial pressure to continue with bad practice in a race to the bottom. It’s a dense and at times exhausting read. But Goldacre has done a decent job of making the issue accessible to a wide audience with a direct interest, from patients to practising doctors and academics. You can skim a lot of the book to get the general gist, or you can read it in details without following the links, or you can dig into research material he drew on and has laid out in meticulous footnotes and citations. He concludes the original edition with practical suggestions about what individual people can do to improve things, often simply by asking questions. I read the second edition, which has a “what happened next” chapter about the reaction to the first edition. As he had predicted, there was a backlash in an attempt to discredit him — but there was also a lot of covert feedback from industry personnel acknowledging the problems and considering how to improve things. While there’s always a “the lurkers support me in email” issue with uncredited sources, he does also offer some examples of companies which have publicly moved to improve transparency. Bad Pharma is an angry but rational examination of a real problem that affects millions of people, including almost anyone reading this review. It’s a worthwhile read, even if it makes for uncomfortable reading for patients, doctors and companies alike.
  • 0 Person fand diese Rezension hilfreich

    0 Personen fanden diese Rezension hilfreich

    0 von 0 Personen fand(en) diese Rezension hilfreich

    Danke für Ihr Feedback!

    Eye opening

    Ben Goldacre has delivered again exposing not just the Drug companies, but the lack of rules and regulations in this field. A must read for anyone affected by this field which in my opinion is everyone.
14

Diesen Titel können Sie auf den folgenden Kobo Apps und Geräten lesen:

  • DESKTOP
  • eREADER
  • TABLETS
  • IOS
  • ANDROID
  • BLACKBERRY
  • WINDOWS